Filing Details

Accession Number:
0001104659-20-030294
Form Type:
4
Zero Holdings:
No
Publication Time:
2020-03-06 18:16:43
Reporting Period:
2019-07-31
Accepted Time:
2020-03-06 18:16:43
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1609550 Inspire Medical Systems Inc. INSP Surgical & Medical Instruments & Apparatus (3841) 261377674
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1737127 Randy Ban C/O Inspire Medical Systems, Inc.
5500 Wayzata Blvd., Suite 1600
Golden Valley MN 55416
Chief Commercial Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2020-03-04 10,000 $1.14 10,000 No 4 M Direct
Common Stock Disposition 2020-03-04 1,801 $84.33 8,199 No 4 S Direct
Common Stock Disposition 2020-03-04 1,673 $85.19 6,526 No 4 S Direct
Common Stock Disposition 2020-03-04 1,613 $86.38 4,913 No 4 S Direct
Common Stock Disposition 2020-03-04 1,730 $87.40 3,183 No 4 S Direct
Common Stock Disposition 2020-03-04 3,044 $88.09 139 No 4 S Direct
Common Stock Disposition 2020-03-04 139 $89.10 0 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (Right to Buy) Acquisiton 2019-07-31 25,000 $0.00 25,000 $67.63
Common Stock Stock Option (Right to Buy) Disposition 2020-03-04 10,000 $0.00 10,000 $1.14
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
25,000 2029-07-31 No 4 A Direct
55,187 2023-09-12 No 4 M Direct
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 167 Indirect By son
Common Stock 166 Indirect By daughter
Footnotes
  1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.
  2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $83.88 to $84.77. The reporting person undertakes to provide Inspire Medical Systems, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $84.91 to $85.43. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $85.94 to $86.73. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  5. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $86.98 to $87.95. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  6. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $88.02 to $88.80. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  7. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $89.04 to $89.12. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  8. The option vests and becomes exercisable as to 25% of the underlying shares on the first anniversary of July 31, 2019 and the remaining 75% of the underlying shares in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates.
  9. The option is fully vested and exercisable.
  10. This option grant was previously reported as having an expiration date of September 11, 2023, which has been revised herein.